Christian S Hinrichs

List of Publications by Year
in descending order

57	9,051	147801	223800
papers	citations	31 h-index	46 g-index

57	57	57	11385
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Determining if T cell antigens are naturally processed and presented on HLA class I molecules. BMC Immunology, 2022, 23, 5.	2.2	4
2	Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade. Head and Neck, 2022, 44, .	2.0	2
3	TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nature Medicine, 2021, 27, 419-425.	30.7	156
4	Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells. , 2021, 9, e002128.		20
5	Advances in Adoptive Cell Therapy for Head and Neck Cancer. Otolaryngologic Clinics of North America, 2021, 54, 761-768.	1.1	9
6	Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis. , 2021, 9, e003113.		12
7	Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypes. Communications Biology, 2021, 4, 1416.	4.4	10
8	Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models. , 2020, 8, e000210.		27
9	T-Cell Receptor Gene Therapy for Human Papillomavirusâ€“Associated Epithelial Cancers: A First-in-Human, Phase I/II Study. Journal of Clinical Oncology, 2019, 37, 2759-2768.	1.6	169
10	Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung Cancer Antigen-1. , 2019, 7, 229.		27
11	Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. , 2019, 7, 119.		35
12	A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirusâ€“associated Epithelial Cancers. Clinical Cancer Research, 2019, 25, 1486-1493.	7.0	174
13	A killer sidekick for antitumor T cells. Science Translational Medicine, 2019, 11, .	12.4	0
14	Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight, 2018, 3, .	5.0	110
15	Human Papillomavirus T-Cell Cross-reactivity in Cervical Cancer. JAMA Network Open, 2018, 1, e180706.	5.9	5
16	Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules. Journal of Translational Medicine, 2018, 16, 13.	4.4	35
17	Can interleukin-15 keep its therapeutic promise?. Science Translational Medicine, 2018, 10, .	12.4	3
18	Self-defeating CAR-Ts protect leukemic cells. Science Translational Medicine, 2018, 10, .	12.4	2

#	Article	IF	Citations
19	Cell-based molecularly targeted therapy: targeting oncoproteins with T cell receptor gene therapy. Journal of Clinical Investigation, 2018, 128, 1261-1263.	8.2	3
20	Regression of Epithelial Cancers Following T Cell Receptor Gene Therapy Targeting Human Papillomavirus-16 E7. Blood, 2018, 132, 492-492.	1.4	9
21	Regression of epithelial cancers in humans following t-cell receptor gene therapy targeting human papillomavirus-16 E7.. Journal of Clinical Oncology, 2018, 36, 3043-3043.	1.6	22
22	Gene transfer delivers (Î²-globin). Science Translational Medicine, 2018, 10, .	12.4	0
23	The hidden agenda for immune escape in colorectal cancer. Science Translational Medicine, 2018, 10, .	12.4	0
24	Abstract 1581: Circulating cell-free DNA for metastatic cervical cancer detection, genotyping and monitoring. , 2018, , .		0
25	T cell receptors communicate by movement. Science Translational Medicine, 2018, 10, .	12.4	0
26	Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science, 2017, 356, 200-205.	12.6	327
27	Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring. Clinical Cancer Research, 2017, 23, 6856-6862.	7.0	70
28	A phase I/II clinical trial of E6 T-cell receptor gene therapy for human papillomavirus (HPV)-associated epithelial cancers.. Journal of Clinical Oncology, 2017, 35, 3009-3009.	1.6	24
29	Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy. Clinical Cancer Research, 2016, 22, 1559-1564.	7.0	28
30	Abstract CT003: A phase I study of an HLA-DPB1*0401-restricted T-cell receptor targeting MAGE-A3 for patients with metastatic cancer. , 2016, , .		0
31	Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirusâ€“Targeted Tumor-Infiltrating T Cells. Journal of Clinical Oncology, 2015, 33, 1543-1550.	1.6	513
32	Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6. Clinical Cancer Research, 2015, 21, 4431-4439.	7.0	147
33	Exploiting the curative potential of adoptive Tâ€cell therapy for cancer. Immunological Reviews, 2014, 257, 56-71.	6.0	422
34	Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer. Science, 2014, 344, 641-645.	12.6	1,460
35	HPV-targeted tumor-infiltrating lymphocytes for cervical cancer.. Journal of Clinical Oncology, 2014, 32, LBA3008-LBA3008.	1.6	9
36	Reassessing target antigens for adoptive T-cell therapy. Nature Biotechnology, 2013, 31, 999-1008.	17.5	181

#	Article	IF	Citations
37	Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer Therapy. Journal of Immunology, 2013, 191, 2217-2225.	0.8	89
38	Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies. Journal of Immunotherapy, 2011, 34, 343-352.	2.4	80
39	Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood, 2011, 117, 808-814.	1.4	272
40	Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice. Clinical Cancer Research, 2011, 17, 5343-5352.	7.0	247
41	A High Molecular Weight Melanoma-Associated Antigenâ€"Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas. Cancer Research, 2010, 70, 3027-3033.	0.9	70
42	Adoptively transferred effector cells derived from naÃ¨ve rather than central memory CD8 ⁺ T cells mediate superior antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17469-17474.	7.1	348
43	Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nature Medicine, 2009, 15, 808-813.	30.7	839
44	Type 17 CD8+ T cells display enhanced antitumor immunity. Blood, 2009, 114, 596-599.	1.4	196
45	Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood, 2008, 112, 4746-4754.	1.4	39
46	IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood, 2008, 111, 5326-5333.	1.4	380
47	Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8061-8066.	7.1	114
48	Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood, 2008, 112, 362-373.	1.4	719
49	Toll-like Receptors in Tumor Immunotherapy. Clinical Cancer Research, 2007, 13, 5280-5289.	7.0	114
50	Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. Journal of Clinical Investigation, 2007, 117, 2197-2204.	8.2	456
51	Interleukin-2-Dependent Mechanisms of Tolerance and Immunity In Vivo. Journal of Immunology, 2006, 176, 5255-5266.	0.8	109
52	Programming CD8+ T cells for effective immunotherapy. Current Opinion in Immunology, 2006, 18, 363-370.	5.5	61
53	Glucocorticoids Do Not Inhibit Antitumor Activity of Activated CD8+ T Cells. Journal of Immunotherapy, 2005, 28, 517-524.	2.4	57
54	Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. Journal of Experimental Medicine, 2005, 201, 139-148.	8.5	636

#	Article	IF	Citations
55	Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. Journal of Leukocyte Biology, 2004, 76, 333-337.	3.3	43
56	Lymphedema Secondary to Postmastectomy Radiation: Incidence and Risk Factors. Annals of Surgical Oncology, 2004, 11, 573-580.	1.5	135
57	The effectiveness of complete decongestive physiotherapy for the treatment of lymphedema following groin dissection for melanoma. Journal of Surgical Oncology, 2004, 85, 187-192.	1.7	32